The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database

Lung, Respiratory and Thoracic Cancer

The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification

J Thorac Oncol

Eng L, Evans WK, Eisele M, Nishimura KK, Land SR, Rami-Porta R, Dresler CM, Asamura H, Fathi JT, Lechtenberg K, Rusch V, Sheikh M, Wynes MW, Zius K, Osarogiagbon RU, Warren GW, Members of the IASLC Staging and Prognostic Factors Group and of the Advisory Boards, and Participating Institutions and the IASLC Tobacco Control and Smoking Cessation Committee

doi: 10.1016/j.jtho.2025.07.002

Lung, Respiratory and Thoracic Cancer

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons

J Thorac Oncol

Hoffmann H, Nicholson AG, Detterbeck FC, Tsao MS, Ostrowski M, Rami-Porta R, Borczuk A, Marino M, Travis WD, Van Schil PE, Edwards J, Members of the R-Subcommittee, and Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards

doi: 10.1016/j.jtho.2024.12.007

Lung, Respiratory and Thoracic Cancer

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG

doi: 10.1016/j.jtho.2024.09.1437

Lung, Respiratory and Thoracic Cancer

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study

Clin Cancer Res

Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR

doi: 10.1158/1078-0432.CCR-24-3658

Lung, Respiratory and Thoracic Cancer

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Lung Cancer

Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC, European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group

doi: 10.1016/j.lungcan.2025.108798

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer

Lung Cancer

Sun F, Banwait MK, Singhal S, Herrmann A, Piotrowska Z, Yun K, Bazhenova L, Ullah AT, Guo EW, Wakelee HA, Neal JW, Das MS, Ramchandran KJ, Roy M, Diehn M, Myall NJ

doi: 10.1016/j.lungcan.2025.108747

Lung, Respiratory and Thoracic Cancer

Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)

Eur J Cancer

Houda I, Naves D, Ulas EB, Lissenberg-Witte BI, Barlo NP, Kastelijn EA, Bouhaddou H, Shaikh R, Dickhoff C, Radonic T, Schneiders FL, Senan S, Damhuis RAM, Bahce I

doi: 10.1016/j.ejca.2025.116042

Related content

The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer

Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)